Basic Information
| LncRNA/CircRNA Name | CADM1-AS1 |
| Synonyms | NA |
| Region | NA |
| Ensemble | NA |
| Refseq | NA |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | |||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | gastric cancer |
| ICD-0-3 | C16 |
| Methods | qPCR |
| Sample | The gastric cancer tissues and para-carcinoma tissues, The gastric cancer tissues and para-carcinoma tissues |
| Expression Pattern | down-regulated |
| Function Description | The expression of lncRNA CADM1- AS1 was significantly decreased in tumor tissues. According to the mean expression of lncRNA CADM1-AS1, the patients were divided into a high expression group and a low expression group, and the expression of lncRNA CADM1- AS1 in gastric cancer was significantly correlated with tumor differentiation, N stage, M stage, and TNM stage. Moreover, the gastric cancer patients with higher expression of lncRNA CADM1- AS1 had a statistically better overall survival (OS) time and progression-free survival (PFS) time. |
| Pubmed ID | 31389606 |
| Year | 2019 |
| Title | LncRNA CADM1-AS1 serves as a new prognostic biomarker for gastric cancer |
External Links
| Links for CADM1-AS1 | GenBank HGNC NONCODE |
| Links for gastric cancer | OMIM COSMIC |